Medical/Pharmaceuticals
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
* Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia * 500,000-1 million people are estimated to be living with FSGS in the territories[1] * Dimerix eligible to ...
2026-06-16 10:53
10056
Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
Designation follows Phase 2 data showing durable transfusion independence and multilineage hematological improvement; full results presented at EHA2026 LEHI, Utah, June 15, 2026 /PRNewswire/ -- Halia Therapeutics, Inc., a clinical-stage biopharmaceutical company developing first-in-class therapie...
2026-06-15 20:00
4255
Six Regional Organisations Sign MoU to Strengthen Asia's Dengue Response as Cases Rise
Announced at the 9th Asia Dengue Summit in conjunction with ASEAN Dengue Day and the first WHO-recognised World Dengue Day, the MoU establishes a regional framework for knowledge-sharing, advocacy and coordinated dengue action. SINGAPORE, June 15, 2026 /PRNewswire/ -- The Asia Dengue Voice an...
2026-06-15 19:30
6685
Kingworld Medicines Group (01110.HK) Signs MOU to Pursue Exclusive Distribution Rights for Two Lingnan Formula Products
Targeting Full-Channel Sales Coverage in Hong Kong, Mainland China and Cross-border E-commerce HONG KONG, June 15, 2026 /PRNewswire/ -- Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", Stock Code: 01110.HK) announced that Morning Gold Medicine Company Limited ("Morning Go...
2026-06-15 13:08
9077
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
* The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. * Post-hoc analysis from the phase 3 SENTRY trial ...
2026-06-14 21:57
6406
Luxel Corporation Appoints KOS, Inc. as Exclusive Distributor in South Korea
FRIDAY HARBOR, Wash., June 13, 2026 /PRNewswire/ -- Luxel Corporation, a global leader in the design and manufacture of ultrathin freestanding polymer and metallized optical bandpass filters, today announced the appointment of KOS, Inc. as its exclusive distribution partner for South Korea, effec...
2026-06-13 06:36
8326
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
BEIJING and BRIDGEWATER, N.J., June 12, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter "Gan & Lee", stockcode: 603087.SH) announced that two of its core pipeline products in the fields of diabetes and obesity treatment have recently achieved positive clinical results. SUPER-3: Insul...
2026-06-12 20:00
8184
KPJ Healthcare Launches First Kidney Transplant Service Within Its Hospital Network
Tawakkal Specialist Hospital expands access to kidney transplantation through coordinated specialist care KUALA LUMPUR, Malaysia, June 11, 2026 /PRNewswire/ -- KPJ Healthcare Berhad ("KPJ Healthcare" or "the Group") has launched its first Kidney Transplant Service within the KPJ network, marking...
2026-06-11 23:46
9132
Lifespan Portfolio Company Rejuvenate Bio Closes $6 Million Financing and R&D Collaboration with Merck Animal Health
Milestone financing and R&D collaboration advances gene therapy programs targeting chronic and age-related diseases in companion animals. NORWALK, Conn., June 11, 2026 /PRNewswire/ -- Lifespan Vision Ventures (LVV), an investment firm focused on therapeutics that improve human healthspan, congra...
2026-06-11 22:20
6348
ZEISS announces successful early implantations of the AT LUCIA toric 721P intraocular lens
The new intraocular lens combines an aspheric bitoric optic with a patented non-constant aberration design (ZO optic) on a fully preloaded, hydrophobic c-Loop platform to help deliver excellent visual outcomes and long-term stability for patients. JENA, Germany, June 11, 2026 /PRNewswire/ -- ZEI...
2026-06-11 19:00
5317
Cynosure Lutronic's XERF™, Worldwide Adoption Accelerates, Now 3x Faster
Now among the fastest-scaling monopolar RF devices worldwide, XERF™ has more than tripled its pace of adoption in recent months with Asia-Pacific and North America leading the surge. SINGAPORE, June 11, 2026 /PRNewswire/ -- Cynosure Lutronic's XERF™, the world's first multifrequency monopolar R...
2026-06-11 14:39
4673
Pantai Hospital Kuala Lumpur Launches AI-Powered Adaptive Radiotherapy System to Advance Personalised Cancer Care in Malaysia
Varian Ethos with HyperSight supports daily treatment adaptation, helping clinicians deliver more precise radiotherapy while reducing unnecessary exposure to healthy tissue KUALA LUMPUR, Malaysia, June 10, 2026 /PRNewswire/ -- Pantai Hospital Kuala Lumpur, part of the IHH Healthcare multination...
2026-06-11 08:41
6323
Frost & Sullivan: Global Pharmaceutical Industry Faces a High-Stakes Reset as AI, Biologics, and Supply Resilience Redefine Growth Through 2031
New Frost & Sullivan analysis reveals that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures LONDON, June 11, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, Growth Opportunities in Global Pharmaceuti...
2026-06-11 04:56
4378
SOPHiA GENETICS Confirms Leadership Transition Ahead of 2026 Annual General Meeting
Ross Muken to assume the role of Chief Executive Officer effective July 1, 2026; Co-founder Dr. Jurgi Camblong nominated for election as Chairman of the Board BOSTON and ROLLE, Switzerland, June 10, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in Ai-driven precision medic...
2026-06-10 20:00
4580
Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders
* Partnership will combine n-Lorem's cutting-edge antisense oligonucleotide (ASO) technology and Servier's R&D expertise with the aim of advancing ASO technology and delivering precision medicine approaches for patients across the world. * Servier strengthens its commitment to rare neurologic...
2026-06-10 16:00
4890
Carestream Launches NEW Lux HD 35 and Lux HD 43 Detectors for Medical Imaging
SHANGHAI, June 10, 2026 /PRNewswire/ -- Carestream announces the availability of its new generation of Cesium Iodide (CsI), glass-free X-ray Detector in markets all over the world, the Carestream Lux HD 35 and Lux HD 43 Detectors. Carestream NEW Lux HD 35 and Lux HD 43 Detectors The Lux HD 35 ...
2026-06-10 10:30
4483
XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on develo...
2026-06-10 10:00
5905
Antengene Receives IND Approval for ATG-201 (CD19 × CD3 TCE) in Autoimmune Disease in China
SHANGHAI and HONG KONG, June 10, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...
2026-06-10 09:00
6880
Lynk Pharmaceuticals' Partner Formation Bio Doses First Participant in Phase 1 Trial of BLKR201 (originally designated as LNK01006), a CNS-Penetrant TYK2 Inhibitor
HANGZHOU, China, SHANGHAI and BOSTON, June 10, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on autoimmune and inflammatory diseases, today announced a significant clinical milestone achieved by its globa...
2026-06-10 08:00
3980
Kelun-Biotech Partner Windward Bio Announces First Patients Dosed in Phase 2 SIRIUS COPD Study of SKB378/WIN378
* COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease * SKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026 * SKB378/WIN378 has the potential to be the firs...
2026-06-09 20:18
7509
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 287 media titles]
2026-09-15 11:00
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 260 media titles]
2026-09-15 19:07
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
12465
